Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs, injections, food, capsules, tablets, traditional Chinese medicines, preparations, pharmaceutical intermediates in China and internationally. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co.,… Read more
Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) - Net Assets
Latest net assets as of September 2025: CN¥1.33 Billion CNY
Based on the latest financial reports, Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) has net assets worth CN¥1.33 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.69 Billion) and total liabilities (CN¥362.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.33 Billion |
| % of Total Assets | 78.56% |
| Annual Growth Rate | 21.31% |
| 5-Year Change | 42.77% |
| 10-Year Change | 386.71% |
| Growth Volatility | 31.0 |
Zhejiang Cheng Yi Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Zhejiang Cheng Yi Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Cheng Yi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.27 Billion | +5.72% |
| 2023-12-31 | CN¥1.20 Billion | +9.69% |
| 2022-12-31 | CN¥1.09 Billion | +9.22% |
| 2021-12-31 | CN¥998.88 Million | +12.73% |
| 2020-12-31 | CN¥886.09 Million | +15.23% |
| 2019-12-31 | CN¥768.96 Million | +14.17% |
| 2018-12-31 | CN¥673.54 Million | +12.34% |
| 2017-12-31 | CN¥599.57 Million | +114.01% |
| 2016-12-31 | CN¥280.17 Million | +7.79% |
| 2015-12-31 | CN¥259.92 Million | +5.25% |
| 2014-12-31 | CN¥246.95 Million | +22.62% |
| 2013-12-31 | CN¥201.40 Million | +13.06% |
| 2012-12-31 | CN¥178.13 Million | +73.62% |
| 2011-12-31 | CN¥102.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Cheng Yi Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11030.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥718.46 Million | 57.02% |
| Common Stock | CN¥327.30 Million | 25.97% |
| Other Comprehensive Income | CN¥140.35 Million | 11.14% |
| Other Components | CN¥73.97 Million | 5.87% |
| Total Equity | CN¥1.26 Billion | 100.00% |
Zhejiang Cheng Yi Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Cheng Yi Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Minerva S.A
SA:BEEF3
|
$321.11 Million |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
$321.39 Million |
|
Linkage Software Co Ltd
SHG:688588
|
$321.48 Million |
|
Anhui Huamao Textile Co Ltd
SHE:000850
|
$321.50 Million |
|
Lion Travel Service Co Ltd
TW:2731
|
$321.02 Million |
|
Cosmecca Korea Co. Ltd
KQ:241710
|
$321.00 Million |
|
MayAir Technology (China) Co. Ltd. A
SHG:688376
|
$320.98 Million |
|
Ooma Inc
NYSE:OOMA
|
$320.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Cheng Yi Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,192,314,263 to 1,260,084,487, a change of 67,770,224 (5.7%).
- Net income of 200,700,773 contributed positively to equity growth.
- Dividend payments of 76,695,496 reduced retained earnings.
- Share repurchases of 67,263,133 reduced equity.
- Other comprehensive income increased equity by 18,858,067.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥200.70 Million | +15.93% |
| Dividends Paid | CN¥76.70 Million | -6.09% |
| Share Repurchases | CN¥67.26 Million | -5.34% |
| Other Comprehensive Income | CN¥18.86 Million | +1.5% |
| Other Changes | CN¥-7.83 Million | -0.62% |
| Total Change | CN¥- | 5.68% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Cheng Yi Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.02x to 3.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.58 | CN¥11.69 | x |
| 2012-12-31 | CN¥1.01 | CN¥11.69 | x |
| 2013-12-31 | CN¥0.82 | CN¥11.69 | x |
| 2014-12-31 | CN¥1.00 | CN¥11.69 | x |
| 2015-12-31 | CN¥1.06 | CN¥11.69 | x |
| 2016-12-31 | CN¥1.14 | CN¥11.69 | x |
| 2017-12-31 | CN¥2.75 | CN¥11.69 | x |
| 2018-12-31 | CN¥2.01 | CN¥11.69 | x |
| 2019-12-31 | CN¥3.25 | CN¥11.69 | x |
| 2020-12-31 | CN¥2.67 | CN¥11.69 | x |
| 2021-12-31 | CN¥3.01 | CN¥11.69 | x |
| 2022-12-31 | CN¥3.32 | CN¥11.69 | x |
| 2023-12-31 | CN¥3.66 | CN¥11.69 | x |
| 2024-12-31 | CN¥3.83 | CN¥11.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Cheng Yi Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.93%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.09%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.37x
- Recent ROE (15.93%) is below the historical average (17.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 13.01% | 6.20% | 0.73x | 2.88x | CN¥3.09 Million |
| 2012 | 16.45% | 11.47% | 0.71x | 2.01x | CN¥11.49 Million |
| 2013 | 18.12% | 13.72% | 0.80x | 1.66x | CN¥16.36 Million |
| 2014 | 21.81% | 16.82% | 0.97x | 1.34x | CN¥29.16 Million |
| 2015 | 22.20% | 18.21% | 0.92x | 1.33x | CN¥31.71 Million |
| 2016 | 24.33% | 21.22% | 0.88x | 1.30x | CN¥40.15 Million |
| 2017 | 11.55% | 20.31% | 0.51x | 1.12x | CN¥9.28 Million |
| 2018 | 14.67% | 17.76% | 0.67x | 1.23x | CN¥30.83 Million |
| 2019 | 17.37% | 19.29% | 0.69x | 1.30x | CN¥55.73 Million |
| 2020 | 18.90% | 21.78% | 0.63x | 1.38x | CN¥77.75 Million |
| 2021 | 17.32% | 24.61% | 0.52x | 1.34x | CN¥72.17 Million |
| 2022 | 14.85% | 24.67% | 0.38x | 1.58x | CN¥52.79 Million |
| 2023 | 13.66% | 24.25% | 0.35x | 1.59x | CN¥43.67 Million |
| 2024 | 15.93% | 28.09% | 0.41x | 1.37x | CN¥74.69 Million |
Industry Comparison
This section compares Zhejiang Cheng Yi Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) | CN¥1.33 Billion | 13.01% | 0.27x | $321.03 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |